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In cultured clear-cell renal carcinoma (CCRCC) 786-0 cells transfected with HIF1α (HIF-1+), HIF-2α (HIF-2+), or empty
vector (EV), no significant diﬀerences were observed in the growth rates in vitro, but when grown in vivo as xenografts HIF-
2α significantly increased, and HIF-1α significantly decreased growth rates, compared to EV tumors. Factors associated with
proliferation were increased and factors associated with cell death were decreased in HIF-2+ tumors. Metabolite profiles showed
higher glucose and lower lactate and alanine levels in the HIF-2+ tumors whilst immunostaining demonstrated higher pyruvate
dehydrogenase and lower pyruvate dehydrogenase kinase 1, compared to control tumors. Taken together, these results suggest that
overexpression of HIF-2α in CCRCC 786-0 tumors regulated growth both by maintaining a low level of glycolysis and by allowing
more mitochondrial metabolism and tolerance to ROS induced DNA damage. The growth profiles observed may be mediated by
adaptive changes to a more oxidative phenotype.
1. Introduction
TheHIFα transcription factors, HIF-1α andHIF-2α, mediate
adaptive responses to tumor hypoxia, as well as regulating
an extensive transcriptional response involving the induction
of genes for angiogenesis, glucose metabolism/cellular ener-
getics, cell growth, metastasis, apoptosis, and extracellular
matrix (ECM) remodelling [1]. HIF-1α and HIF-2α, despite
some overlapping eﬀects, can uniquely regulate distinct
genes [2]. HIF-1α for example is primarily involved in
glucose metabolism by upregulating glycolytic enzymes [3,
4] whilst limiting pyruvate uptake by the mitochondria
[5, 6] and down regulating the electron transport chain
(ETC) activity by altering the subunit composition of COX,
minimising ROS generation [7]. In contrast, HIF-2α is
uniquely involved in tumor growth and cell cycle progression
through interaction with c-Myc [8, 9].
The most direct link between genetic events that pre-
dispose to cancer and activation of the HIF pathway is
observed in tumors associated with inactivation of the von
Hippel-Lindau (VHL) tumor suppressor gene, particularly
VHL-associated clear-cell renal cell carcinoma (CCRCC) (for
review see [10]). The pseudohypoxic VHL-defective CCRCC
cells show a bias toward HIF-2α, and overproduction of
HIF2α (but not HIF1α), has been found to be suﬃcient to
override the tumor suppressor function of VHL in xenograft
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studies [11–13]. HIF-2α expression (in a mouse model of
CCRCC) is necessary for the development of the typical
clear-cell phenotype, demonstrating the important role of
HIF-2α in CCRCC [14].
Using retroviral transfection in 786-0 cells, Raval et
al. [12] confirmed that exogenous expression of HIF-
1α upregulated transcriptional products involved in pH
regulation (CAIX) and cell fate (BNIP3), whereas expression
of HIF-2α upregulated a diﬀerent set of proteins which
were involved in cell proliferation (cyclin D1), cell growth
(TGF-α), and angiogenesis (VEGF). However, the in vitro
studies demonstrated no diﬀerences in the proliferation rate
between 786-0 cells that either exogenously expressed HIF1α
(HIF-1+), overexpressed HIF-2α (HIF-2+) or were infected
with empty vector (EV) (control cells). But when these
manipulated 786-0 cells were grown in vivo as xenografts, a
diﬀerent tumor growth profile emerged showing that HIF-
2α caused significantly increased growth rates and HIF-1α
caused significantly decreased growth rates when compared
to EV tumors. Similar findings (HIF-2α facilitating tumor
growth in vivo) have also been made in two nonepithelial
tumors, teratoma [13] and neuroblastoma [15] in vivo.
However, apart from the growth curves, few studies have
been reported that investigate the role of HIF-2α in epithelial
cancers in vivo (for review see [16]). Most epithelial cancer
cells rely on HIF-1α transcriptional products to mediate
tumor metabolism including the eﬀect first described by
Warburg [17] more than 80 years ago that leads to the repro-
gramming of tumor cells from mitochondrial respiration
to aerobic glycolysis (see [18–20] for review). The human
VHL -/- clear-cell renal cancer cell line, 786-0, provides a
model for investigating the eﬀects of both HIFα isoforms,
particularly HIF-2α, on tumor growth and metabolism in
vivo, since it constitutively expresses only HIF-2α. To further
understand the role of HIF-2α in vivo, we have investigated
the eﬀects of HIF-2α expression not only on CCRCC 786-0
tumor growth, but also on metabolic adaptation to tumor
progression by using Magnetic Resonance Spectroscopy
(MRS) methods both noninvasively in vivo and ex vivo on
tumor extracts.
The rationale for using 786-0 line in our experiments
is that CC-RCC comes in two HIF types that is HIF-2 only
and HIF-2 + HIF-1. Therefore, using a CC-RCC, HIF-2 only
expressing cell line is appropriate to investigate the role of
HIF-1 in CC-RCC tumour growth/biology as well as the
eﬀects of HIF-2 overexpression on an endogenous HIF-1
null background (see [21]). Expression of HIF-2α resulted
in a significant increase in tumor growth rate similar to
that observed previously [12] whilst HIF1+ tumors grew
even more slowly than EV tumors. Immunohistochemistry
(IHC) was chosen rather than Western Blotting because
the necrosis and heterogeneity of in vivo tumors causes
poor reproducibility. IHC allows heterogeneity to be scored
and the extent of protein expression to be determined in a
semiquantitative fashion. Using a combination of immunos-
taining and/or 1H or 31P Magnetic Resonance Spectroscopy
(MRS), we also demonstrate that expression of HIF-2α
decreased the expression of HK-II, LDH5 and pyruvate
dehydrogenase kinase 1 (PDK1) with a concomitant increase
in pyruvate dehydrogenase (PDH) expression. This, together
with higher glucose and lower lactate and alanine levels
found in the HIF-2+ tumors (compared to both EV and
HIF-1+ tumors), results in a more oxidative, DNA damage-
tolerant phenotype that supports enhanced tumor growth,
similar to the Sporadic VHL-deficient clinical subtypes of
CCRCC described by Gordan et al. [21].
2. Materials and Methods
2.1. Human Clear-Cell Renal Cancer Cell Lines. Stable
polyclonal pools of G418 selected 786-0 renal cancer cells
expressing the relevant HIFα isoform (HIF-1+) were pro-
duced in vitro from the same pool as previously described
[12]. Polyclonal pools retrovirus-infected with the pBMN-
Z-IRES-Neo-based HIF-1α, HIF-2α (HIF-2+), or control
(EV), were released by trypsinization and subsequently
resuspended in PBS.
2.2. Xenografts. 786-0 cells (1 × 107) transfected with HIF-
1or 2α or control in 100 μl PBS were injected subcutaneously
into the dorsal flanks of nu/nu mice. Three cohorts were
generated. Two consisting of 21 mice with 7 in each group
(HIF-1+, HIF 2+ and EV) for growth, immunohistochem-
istry and histology; and one consisting of 15 mice with 5
in each group (HIF-1+, HIF 2+ and EV) which were grown
to at least 500mm3, the minimum size possible for in vivo
Magnetic Resonance Spectroscopy experiments.
Tumor size was measured bidirectionally in all experi-
ments, twice per week using calipers, with the longest dimen-
sion (l) and shortest dimension (s) measured postimplan-
tation. Tumor volume (mm3) was calculated by measuring
length, width and depth using callipers and 1∗w∗d∗(π/6).
2.2.1. Tumor Processing. The mice from cohort (1 and 2)
were sacrificed by cervical dislocation at day 42, the tumors
bisected with one-half snap-frozen for storage at −80◦C,
and the other half-embedded in paraﬃn. The mice from
cohort (3) were anesthetized with a single i.p. injection of
a Hypnovel/Hypnorm/water (1 : 1 : 2) mixture as previously
described [22] prior to the MR experiment (details below).
At the end of the experiment the tumors were freeze-clamped
and stored at −80◦C. Subsequently the frozen tumors were
extracted in 6% perchloric acid, as previously described
[23] and the neutralized extracts were freeze-dried and
reconstituted in 1ml deuterium oxide for high resolution
MRS. Cyrostat sectioning of frozen tumors was performed
for mouse CD31 staining as previously described [24], and
Fuhrman’s criteria were applied to histological grading for
characterization of nucleoli morphology [25].
2.2.2. Immunohistochemistry. Tumors were prepared for
immunohistochemistry as follows. Briefly, endogenous tissue
peroxidase activity was blocked using two drops of 0.3%
hydrogen peroxide (1 : 100 dilution of 30% H2O2 stock
(BDH Laboratory Supplies, Poole, UK) in distilled water),
to cover each section. After two rounds of immersion
in PBS, for 5 minutes each, 2.5% normal horse serum
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(Normal horse serum concentrate—Vector Laboratories Inc,
California, USA, diluted in PBS) was applied to each section
for 30 minutes at room temperature to prevent nonspecific
primary antibody binding.
Primary antibodies were directed against HIF-1α, HIF-
2α and CAIX; mouse monoclonals (ESEE122), (237/B5) and
(M75), respectively, University of Oxford. Ki67, Cyclin D1:
mouse monoclonals (MIB-1) and (DSC-6), and GLUT-1:
rabbit polyclonal; DAKO, Ely, UK: Cleaved caspase-3; rabbit
monoclonal, R+D Systems, UK; BNIP3: mouse monoclonal
(ANa40) SIGMA, UK; CD10: mouse monoclonal (56C6),
Abcam, UK; VEGF: SP28, rabbit monoclonal antibody,
Abcam,UK; Phospho-Ser473 Akt and PTEN: rabbit mon-
oclonals 736E11 and 138G6 respectively, Cell Signalling,
USA; Hexokinase-II: rabbit polyclonal, Chemicon, USA;
LDH5: sheep polyclonal, Abcam, UK; PDH E2 Complex:
mouse monoclonal (15D3), Invitrogen, USA; PDK-1: goat
polyclonal, Santa Cruz, USA; TOM-20: mouse mono-
clonal (F10), Santa Cruz, USA; PGC-1 β: rabbit poly-
clonal, Santa Cruz, USA; γH2AX (phospho-Ser139 Histone
H2A.X): Rabbit Monoclonal, 20E3, Cell Signaling, USA;
8-Hydroxyguanosine (8-OH-G): goat polyclonal, Alexis
Biochemicals, Nottingham, UK; OGG1 Rabbit polyclonal
(ab204) Abcam, UK.
The Envision-HRP ChemMate polymer kit (DAKO, Ely,
UK) was used for detection of either mouse and rabbit
monoclonal or rabbit polyclonal primary antibodies, as
per the manufacturer’s instructions. Where applicable, the
relevant secondary antibodies of antigoat (P0160, DAKO, Ely,
UK), antisheep (ab6747, Abcam, UK) and antirat (P0450,
DAKO, Ely, UK) were used.
The majority of primary antibodies were detected with
a 3,3-diaminobenzidine (DAB+) chromogenic substrate sys-
tem as part of the Envision kit. Nuclei were counterstained
with Haemotoxylin before mounting onto plastic coverslips
with AquaMount (Gurr GmBH, Strasbourg, Germany).
For Ki67 (MIB-1 clone) detection, ChromogenSG (Vector
Laboratories Inc., California, USA) was used and the nuclei
counterstained with Nuclear Fast Red (Sigma-Aldrich, St.
Louis, USA). Sections treated in both these ways were dehy-
drated through methanol and xylene, before haemotoxylin
counterstaining and mounting with DPX.
2.2.3. Assessment of Tumor Immunostaining. Each tumor
section was assessed blindly and independently by two
observers. Photomicrographs were taken at x100 hpf. Semi-
quantitative analysis of protein expression was performed
using a modified “Histoscore” method, as previously
described [26]. For Ki67 and Cleaved caspase-3 scoring,
positive and negatively stained cells within 5 individual
tumor areas, consisting of 100 cells each, were scored [27].
Tumor necrosis was quantified as the % area of tumor
replaced by necrosis, as identified by light microscopy [28].
CD31+ Chalkley Vessel Count (CVC) was the average value
from the three fields [29].
2.3. Magnetic Resonance Spectroscopy (MRS). Anesthetized
mice were placed in the bore of a Varian 4.7 T nuclear
magnetic resonance (NMR) spectrometer at St. George’s
University of London, and tumors were positioned in the
center of a 15-mm two-turn 1H surface or 31P MRS coil.
Voxels were selected from scout gradient echo images,
and localized shimming yielded linewidths of the order
of 20–30Hz. The PRESS localization method with water
suppression with a repetition time of 2 seconds was used
to detect choline [30]. For 31P MRS, image selected in
vivo spectroscopy (ISIS) [31] localised spectra of tumors
were acquired. MRUI software was used for all spectral
processing programs, including preprocessing, fitting and
quantification of peak areas of the observed metabolites.
1H MR spectra of the neutralised tumor extracts were
obtained using a Bruker 600MHz spectrometer (pulse angle
45◦; repetition time, 3.5 seconds). The water resonance
was suppressed by gated irradiation centred on the water
frequency. 25 μl of 10mM Sodium 3-trimethylsilyl-2,2,3,3-
tetradeuterpropionate (TSP) was added to the samples for
chemical shift calibration and quantification. The pH was re-
adjusted to pH 7 prior to 1H MRS.
2.3.1. Statistics. For analysis of the immunohistochemical
expression of individual proteins between all tumor groups,
the nonparametric Kruskal-Wallis (ANOVA) test was used.
Results from one cohort were displayed as histograms with
standard error of the mean (SEM) in the figures. Dunn’s
post hoc test for all data sets was calculated if P < .05
and displayed in the figures. Immunohistochemical protein
expression between specific pairs of 786-0 tumor groups
was compared using the Mann-Whitney unpaired t-test,
where mentioned in the text. The Spearman rank testing was
used to demonstrate correlations between non-parametric
variables. For the MRS data a two-tailed t test was used
for significance levels. Significant results were designated if
P < .05.
3. Results
3.1. Eﬀect of Transfection of Specific Retroviral HIFα Isoform in
CCRCC 786-0 Xenografts. We have previously demonstrated
[12] that the appropriate HIFα isoform protein is expressed
after retrovirally-mediated infection of specific HIFα isoform
constructs within a bicistronic IRES-neo cassette, in vitro.
These in vitro findings were confirmed in vivo in tumors
grown subcutaneously as xenografts in mice in all three
groups. HIF-1α expression was identified only in the HIF-1+
tumors, and only within the nuclear compartment, whereas
the EV and HIF-2+ tumors showed no staining for HIF-1α
(Figures 1(a)–1(d)).
However, HIF-2α expression was identified in both
nuclear and cytoplasmic compartments in all 3 tumor
groups (Figures 1(e)–1(h)), but showed a significant increase
only within the nuclear compartment of HIF-2+ tumors
(Figure 1(g)). No significant changes in HIF-2α expression
were seen in either compartment of the HIF1+ or the EV
tumors (Figures 1(e)–1(f)). A further cohort (not shown in
figures) of in vivo tumors confirmed the findings of HIF-1
and HIF-2α expression as well as a similar growth pattern in
the 3 tumor types.
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Figure 1: Features of CCRCC 786-0 tumors. (a–d) (x100 hpf) HIF-1α nuclear staining only (∗P < .0001). (e–h) Diﬀerential HIF-2α nuclear
staining (∗P = .0004). (i) Clear-cell/sarcomatoid morphology (x40 hpf). (j) CD10+ staining typical of clear-cell RCC lineage (x100 hpf). (k)
PTEN staining; positive staining only identified in murine fibroblasts (x100 hpf). (l) Akt staining, (m) Phospho-Ser473 Akt staining (highest
in HIF-2+ tumors). ∗P values were calculated using an ANOVA test.
3.2. Eﬀect of HIFα Isoform Expression on Grade and Phenotype
of CCRCC 786-0 Xenografts. 21 tumors were evaluated
after H+E staining, and each exhibited a high Fuhrman’s
tumor grade of either 3 or 4, with the majority of tumors
demonstrating sarcomatoid dediﬀerentiation. There were no
diﬀerences in Fuhrman’s grade between the three tumor
groups (a representative example is shown in Figure 1(i)).
Only one tumor (an EV tumor) was morphologically wholly
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clear-cell and one tumor (HIF-2+) was completely replaced
with sarcomatoid de-diﬀerentiation which is a clinically
recognised variant of high grade tumors. However despite
their sarcomatoid de-diﬀerentiation the tumours retained
expression of typical clear-cell renal cancer markers such as
CD10 (Figure 1(j)), pancytokeratin and vimentin positive
expression, on a CK-7 negative background (data not
shown). 786-0 cells were PTEN negative (Figure 1(k)), but
the surrounding murine fibroblasts demonstrated positive
staining. This finding was confirmed by the high levels
of phospho-Ser473 (activated) Akt expression in the 786-0
cells of the EV tumors (Figure 1(l) and 1(m)). Expression
of activated Akt was increased in the HIF-2+ tumors
compared to EV and HIF-1+ tumors. This may be because
expression of TGFα was increased in the HIF-2+ tumors
with a similar increase in activated EGFR (Tyr1173-EGFR)
expression, compared with EV and HIF-1+ tumors (data not
shown).
3.3. Eﬀect of HIFa Expression on Tumor Proliferation and
Apoptosis in 786-0 Xenografts. In contrast to the growth
patterns in vitro where the 3 cell types demonstrated similar
proliferation rates [12], growth patterns in vivo showed that
there were significant diﬀerences between HIF-1+, HIF-2+
and EV 786-0 tumors (Figure 2(a)). The diﬀerences in overall
growth between the 3 tumor groups were dependent on
the lag phase for each tumor group as well as the rate of
tumor growth. TheHIF-2+ tumors had the shortest lag phase
(21 days) followed by the EV tumors (27 days) with the
HIF-1+ tumors taking the longest time (>32 days). Once
the lag phase was over, the actual rates of growth were
45 ± 5.4mm3/day for HIF-2+ (P = .09 compared to EV),
35 ± 3.3mm3/day for EV tumors (P = .0007 compared to
HIF-1) and 18±4.0mm3/day for HIF-1+ tumors. There were
no significant diﬀerences in necrosis between the diﬀerent
tumor types (Figure 2(b)).
The EV tumors demonstrated the highest Ki67 (MIB-
1%) proliferation rates in comparison to both the HIF-
1+ and HIF-2+ tumors (P = .0006) (Figures 3(a)–3(d)).
Cyclin D1 expression however was highest in the HIF-
2+ tumors (P = .0010) (Figures 3(e)–3(h)). The overall
rates of apoptosis measured by cleaved-caspase 3 were very
low (<0.5%) in all the tumor groups (Figure 3(i)–3(l)).
The HIF-1+ tumors had the highest rate of apoptosis (∼
0.4%) compared to controls (P = .0002), whereas the HIF-
2+ tumors had only 0.1% compared to the EV tumors
with ∼0.25%. Because the apoptotic rates were so low,
we also considered potential regulators of alternative death
pathways, such as BNIP3, which has been implicated in
cancer cell autophagy [32, 33]. The intergroup expression of
BNIP3 demonstrated that HIF-2+ tumors showed the lowest
expression and HIF-1+ tumors the highest (P = .0002)
(Figures 3(m)–3(p)). However, as previously mentioned
there were no significant diﬀerences in the level of tumor
necrosis between the diﬀerent groups (Figure 2(b)).
3.4. Eﬀect on Factors Related to Glucose Metabolism; Glut-
1, HKII, LDH. Expression of GLUT-1 was attenuated in
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Figure 2: (a) Growth curve kinetics of 786-0 CCRCC tumors in
vivo. (b) Areas of tumor necrosis (%) ∗P > .1. ∗P values were
calculated using an ANOVA test.
the HIF-2+ tumors (Figures 4(a)–4(d)) in comparison to
the other two tumor groups (P = .01), in contrast to
the in vitro findings by Raval et al. [12]. Expression of
two glycolytic enzyme proteins, HK-II (Figures 4(e)–4(h))
and LDH5 (Figures 4(i)–4(l)), was significantly lower in the
HIF-2+ tumors in comparison to both the HIF-1+ and EV
tumors, whereas there was no diﬀerence in the expression
of these glycolytic enzymes between HIF-1+ tumors and EV
tumors.
3.5. Metabolites Measured by 1H MRS and 31P of 786-0
Xenografts and in Tumor Extracts. 1H MRS of in vivo tumors
demonstrated higher levels of free choline (which resonates
at∼3.2 ppm) in the HIF-2+ tumors (Figure 4(m)) compared
to HIF-1+ and EV tumors. After in vivo scanning the tumors
were freeze-clamped and metabolites were measured at high
field in tumor extracts (which gives better resolution than in
vivo) by 1HMRS (Figure 4(n) and Table 1). The MR spectra
shown in Figure 4(n) are representative samples of various
spectral regions of the high resolution spectra obtained from
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Figure 3: (x100 hpf). Growth and death markers in CCRCC 786-0 tumors. (a–d) Ki67 proliferation index (∗P = .0006). (e–h) Cyclin D1
expression (∗P = .001). (i–l) Apoptosis as measured by cleaved-caspase-3% index (∗P = .0002). (m–p) BNIP3 expression (cytoplasm only)
(∗P = .0002). ∗P values were calculated using ANOVA test.
the extracts of each tumor type. The significantly higher
levels of choline/phosphocholine (PC) found in extracts of
HIF-2+ tumors reflected the raised choline found in the
tumors in vivo by 1H MRS. In vivo 31PMRS of the tumors
showed no significant diﬀerences between the parameters
ATP, PME, PDE, Pi (data not shown). Using Pi spectral shift
analysis [34], similar values for intracellular pH (pHi) were
found in all 3 tumor groups. Similar to the in vivo results,
no diﬀerences were observed in the high energy phosphates
(ATP+ADP) between the diﬀerent tumor types (Table 1).
Signals from glucose, creatine (tCr), and taurine were
also significantly higher in the HIF-2+ tumors, whereas
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Table 1: Metabolite levels measured by 1H MRS in 786-0 tumor
extracts.
Metabolite EV HIF-1+ HIF-2+
Leucine 0.13± 0.01 0.17± 0.02 0.17± 0.01a
Iso Leucine 0.06± 0.01 0.08± 0.005 0.08± 0.005a
Lactate 5.13± 0.85 5.43± 0.51 2.54± 0.58a,b
Alanine 0.84± 0.06 0.88± 0.05 0.63± 0.04a,b
Choline 0.17± 0.02 0.22± 0.04 0.29± 0.05a
PC 0.73± 0.09 0.66± 0.14 1.14± 0.05a,b
Taurine 13.96± 1.55 13.02± 0.92 16.70± 0.66b
Cr 1.26± 0.14 1.46± 0.15 2.00± 0.17a,b
Glucose 0.63± 0.10 0.73± 0.12 1.19± 0.29a
ATP+ADP 0.91± 0.20 0.95± 0.13 1.14± 0.15
Metabolites expressed as μmol/g wet weight tissue (n = 3–5). adenotes
statistically significant diﬀerent from EV and bdenotes statistically signif-
icant diﬀerence (P < .05) from HIF-1+. A two-tailed t test was used for
significance levels.
alanine and lactate were significantly lower compared to the
HIF-1+ and EV tumors. This is more clearly demonstrated in
the detailed analysis of the metabolites shown in Table 1 and
described below. These data imply a more oxidative and less
glycolytic phenotype for the HIF-2+ tumors.
3.6. Eﬀects on Factors Related to Mitochondrial Regulation
and Free Radical Damage; PDH, PDK-1, TOM-20, 8-
OH-Guanosine and OGG1. PDH (Figures 5(a)–5(d)) was
upregulated and PDK-1 (Figures 5(e)–5(h)) down-regulated
in the faster growing HIF-2+ tumors. Higher expression
levels of the cellular mitochondrial load marker, TOM-20
(Figures 5(i)–5(l)) was also seen in the HIF-2+ tumors
and in turn this was mirrored by an increase in expression
of the mitochondrial biogenesis regulator, PGC-1β (data
not shown). Overall, this is consistent with an increase in
mitochondrial biosynthesis and activity.
The HIF-2+ tumors were also under a comparatively
greater degree of oxidative stress, as manifest by higher
levels of 8-OH-guanosine staining compared to the other
two tumor groups (Figures 6(a)–6(d)). However immunos-
taining of γH2A.X (Figures 6(e)–6(h)) showed lower levels
indicating less DNA damage in HIF2+ than in HIF1+ or EV
tumors. Expression of OGG1 (a DNA repair enzyme) was
higher in the HIF-2+ tumors compared to HIF-1+ and EV
tumors (Figures 6(i)–6(l)).
3.7. Eﬀects on Factors Related to Neoangiogenesis. VEGF,
identified only in the cytoplasm of tumor cells, was higher
in the HIF2+ tumors compared to HIF1+ and EV tumors
(Figures 7(a)–7(d)). The Chalkley Vessel Count (CVC) using
an anti-mouse CD31 antibody, was also higher in the HIF-2+
tumors compared to both HIF-1+ and EV groups (Figures
7(e)–7(h)), which was consistent with the pattern of VEGF
expression.
4. Discussion
The tumor grade of 786-0 tumors does not alter with
diﬀerential HIFα isoform expression on a HIF-2α-only
expressing background, whether grown as cultured cells or
as xenografts that demonstrate a high grade phenotype and
characteristic morphology. Although the patterns of HIFα
isoform expression in vivo were similar to those found in the
CCRCC 786-0 cells in vitro [12], there were some diﬀerences
between the levels of specific transcription factors expressed
in vitro and in vivo. The expression of BNIP3, cyclin D1,
TGFα and VEGF in the in vivo model were similar to HIFα
isoform expression found in vitro. However the expression
of GLUT-1 was comparatively lower in the HIF-2+ tumors
in vivo (see below for discussion) consistent with a more
oxidative phenotype.
4.1. Tumor Growth and Related Death Pathways. This in vivo
study showed that the growth of CCRCC 786-0 tumors was
biphasic, with an initial growth lag phase followed by growth
acceleration. The HIF-1+ tumors, which were overall the
slowest growing of the three groups, had the longest lag
phase whereas the EV tumors started to grow at day 27, and
the HIF-2+ tumors at day 21. The lag times and growth
rates in vivo were similar to those observed previously [12].
These diﬀerences in early growth may reflect stress of a poor
blood supply which could have aﬀected early establishment
of the tumors, since the HIF-2+ tumors had the highest levels
of CD31+ angiogenesis and VEGF, but the shortest initial
growth lag phase compared to EV and HIF-1+ tumors.
Tumor growth is a balance between cellular proliferation
and cell death. The increased levels of cyclin D1, an
important regulator of cell cycle progression, were seen in
the faster growing HIF-2+ tumors, but surprisingly they
had the lowest proliferation index (Ki67) and very low
levels (<0.5%) of apoptosis in vivo. This may be the result
of two independent background factors. Activated Akt is
constitutively expressed in the 786-0 xenografts, due to the
PTEN -/- status, facilitating tumor growth [35] and an
antiapoptotic phenotype [36]. Since the levels of necrosis
were similar between tumor groups, alternative cell death
mechanisms, such as autophagy, were considered to explain
the diﬀerences in growth between the tumor types. BNIP3
levels were significantly lower in HIF2+ tumors in vivo,
and were consistent with the in vitro results of Raval et
al. [12] showing that over-expression of HIF-2α attenuated
BNIP3 expression. Since both HIF-1+ and EV tumors had
significantly higher levels of BNIP3, and since their levels
of apoptosis were very low, we hypothesize that BNIP3
induces autophagic cell death in this 786-0 model as a
default death mechanism. In addition, phosphocholine and
glycerophosphocholine were highest in the HIF2+ tumors
compared to HIF-1+ and EV tumors. Usually (although not
always [37]) high levels of PC and GPC are associated with
increased proliferation and growth, but in the present study
the HIF-2+ tumors had lower proliferation (Ki67) but higher
growth rates, compared to controls. The findings in the HIF-
2+ tumors combined with low apoptosis and autophagy are
in contrast to the tumor suppressor eﬀects reported in both
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Figure 5: Markers of oxidative phosphorylation andmitochondrial load in CCRCC 786-0 tumors. (a–d) PDH expression (∗P = .003). (e–h)
PDK-1 expression (∗P = .006). (i–l) TOM-20 (mitochondrial marker) expression (∗P = .004). ∗P values were calculated using an ANOVA
test.
neuroblastoma [38] and colon cancer [39] xenograft models,
as well as a rat GS9L orthotopic glioma model [40].
This discrepancy in the growth profile between the 786-
0 CCRCC model and other non-CCRCC model systems
may lie in the diﬀerent HIFα backgrounds of the parental
cell lines which are diﬀerent. The 786-0 CCRCC cell line
only expresses HIF-2α, whereas both the N1E-115 neurob-
lastoma cell line [38] and the SW480 colon cancer line
[39] endogenously expressed HIF-1α, as well as HIF-2α. It
is the expression of HIF-1α in both of these other model
systems that is thought to facilitate tumor growth, and over-
expression of HIF-2α antagonises this eﬀect. Similarly, in the
rat GS9L orthotopic model, the tumor suppressive eﬀect of
HIF-2α over-expression was caused by apoptosis [40].
However in the CCRCC 786-0 model, we suggest that
over-expression of HIF-2α regulates growth both by main-
taining some glycolysis, albeit at a lower level, allowing
more mitochondrial metabolism (higher PDH, lower PDK)
and tolerance to DNA damage (γH2A.X) resulting from
increased ROS (8-OH-guanosine) production.
A recent study by Gordan et al. [21] raises the possibility
that HIF1α acts as a tumor suppressor, and our data showing
decreased growth rate of the HIF1+ compared to EV tumors
seem to support this suggestion [10].
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Figure 6: Oxidative stress and DNA damage/repair in CCRCC 786-0 tumors. (a–d) 8-OH-Guanosine staining (oxidative stress marker)
(∗P = .001). (e–h) γH2A.X staining (double-stranded DNA damage) (∗P = .004). (i–l) OGG1 expression (∗P = .006). ∗P values were
calculated using an ANOVA test.
4.2. Tumor Metabolism and Its Consequences. In non-
CCRCC cells in vitro, Akt signalling has also been demon-
strated to positively regulate glycolysis in a HIF-1α indepen-
dent manner [41] mainly through mediating the localization
of GLUT-1. HIF-2+ tumors had lower expression of GLUT-1
in comparison to the EV tumors, despite supranormal levels
of activated Akt. These findings are in contrast to the in vitro
findings of Raval et al. [12] who demonstrated that HIF-
2α was the principal regulator of GLUT-1 expression. An
explanation for this discrepancy between the in vitro and in
vivo results could be that GLUT-1 expression is also sensitive
to changes in intracellular glucose concentration. Higher
concentrations of glucose were found in the HIF-2+ tumors,
and could have attenuated GLUT-1 localization. This higher
tumor glucose level along with decreased expression of
HK-II and LDH5 and lower levels of lactate and alanine
in the HIF-2+ tumors compared to both the EV and HIF-
1+ tumors, suggested a decreased glycolytic flux in HIF2+
tumors compared to HIF-1+ and EV tumors. However HIF-
1α (in an endogenous HIF-2α-only background) in vivo,
appeared to have no eﬀect on GLUT-1 expression since there
were no diﬀerences between glucose concentrations and
GLUT-1 expression in HIF-1+ and EV tumors. Interestingly,
Cyclin D1 (which was higher in the HIF2+ tumors) has been
shown in an in vivomousemammary cancermodel to reduce
the expression of both HK-II and LDH5 [42].
HIF-1 modulates multiple key metabolic pathways to
optimize use of O2 and glucose in response to changes in
availability of these substrates, in order to most eﬃciently
generate ATP without excessive generation of ROS [7]. PDH
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Figure 7: Markers of angiogenesis in CCRCC 786-0 tumors. (a–d) VEGF expression (∗P = .003). (e–h) Murine CD31+ vessel staining
(∗P = .001). ∗P values were calculated using an ANOVA test.
is the key enzyme that determines whether pyruvate formed
during glycolysis from glucose will be metabolised to lactate
or oxidised in the TCA cycle. Its regulator, PDK, has been
shown to be expressed in a HIF-1α dependent manner [5, 6].
PDK negatively regulates PDH by phosphorylation, and in
EV tumors the level of aerobic glycolysis was characterised
by high PDK and low PDH indicating the basal level of
glycolysis in these tumors. A similarly high PDK, low PDH
was also found in HIF-1+ tumors, suggesting that the basal
level of aerobic glycolysis in EV 786-0 cells in vivo cannot be
increased by exogenous expression of HIF-1α; alternatively
this may be due to mutually interacting eﬀects of the pVHL
- /- [43] and PTEN -/- status [44] of the parental 786-0 cell
line.
In HIF-2+ tumors, in contrast, PDK-1 was decreased
and PDH was increased suggesting that the HIF2+ tumors
rely on a less glycolytic, more oxidative metabolism. We
hypothesize that increased oxidation would supply more
reducing equivalents for the electron-transport chain (ETC),
increase mitochondrial O2 consumption and thus increase
the ATP supply to support the greater growth rate of
the HIF2+ tumors. In support of this hypothesis were
the findings of higher levels of TOM-20 (mitochondrial
load) and lower BNIP3 levels in HIF-2+ tumors, consistent
with a higher mitochondrial mass, less mitophagy, and up-
regulation of respiration, the converse of what was found
with HIF-1α expression [45].
Since activated Akt is known to have the paradoxical
eﬀect of increasing mitochondrial O2 consumption and
subsequently facilitating ROS generation [46], it could be
postulated that the supranormal levels of activated Akt status
and the metabolic shift to greater oxidative metabolism in
the HIF-2+ tumors is mainly responsible for the higher levels
of 8-OH-Guanosine immunostaining (high ROS stress)
identified in these tumors. In spite of high ROS, γH2A.X
levels and OGG1 indicated resistance to DNA damage in
the HIF2+ tumors. These findings (summarised in Table 2)
are in agreement with Gordan et al. [8, 9] who have shown
that HIF-2α promotes cell cycle progression by enhancing
c-Myc mediated cyclin D2, leading to enhanced growth
and resistance to DNA damage. This was not achieved
by modulating c-Myc levels, but by its interactions with
partners. Although we did not stain for c-Myc in the
786-0 xenografts, it is highly likely that HIF-2α-mediated
enhancement of c-Myc activity played a role in the xenografts
studied here.
5. Conclusions
Tumor metabolism represents the end point of many signal
cascades recruited by oncogenic activation. HIFα isoforms,
particularly HIF-1α, have been shown to be key regulators
of aerobic glycolysis in cancer cells. This is because HIF-1α
not only mediates the transcription of cytoplasmic glycolytic
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Table 2: Overview of molecular characteristics of HIF-1α and
HIF-2α expression on CCRCC 786-0 xenografts compared to EV
xenografts.
Parameter Marker HIF-1+ HIF-2+
Growth volume  
Ki67 ↓ ↓
Cyclin D1 — 
Apoptosis Caspase-3 <0.5% <0.5%
Autophagy BNIP3 ↑ 
Glycolysis GLUT-1 — 
HK II — 
LDH5 — 
Lactate — 
Glucose — 
Mitochondrial
Respiration
PDH/PDK ↓ 
TOM-20 — 
ROS 8-OH-guanosine ↓ ↑
DNA γH2A.X ↑ 
damage/repair OGG1 — 
Angiogenesis VEGF — 
CD31 — 
enzymes and PDK-1, which phosphorylates and inactivates
PDH, but also attenuates mitochondrial function by down
regulating ETC activity, leading to a consequent reduc-
tion of oxidative phosphorylation [7]. However, it could
be speculated that expression of HIF-2α, in manipulated
CCRCC 786-0 tumors, overcomes the HIF-1α eﬀects, which
results in a more oxidative tumor phenotype that supports
a more aggressive phenotype. These results (see Table 2) are
in general agreement with the recent findings of Gordan
et al. [8] who showed that HIF-2α expression in pVHL-
deficient CCRCC tumor lines potentiated c-Myc activity,
resulting in enhanced growth and resistance to replication
stress. We propose that the growth profiles observed in the
HIF-1+ and HIF-2+ tumors that we have studied may be
mediated by HIF-1α inhibition of the c-Myc oncoprotein
(slowing HIF-1+ growth) whilst HIF-2α potentiates c-
Myc transcriptional activity (HIF-2+) and promotes tumor
growth by an adaptive change to amore oxidative phenotype.
In addition, the overall results from our study are consistent
with the findings of Gordan et al. [21] who showed that
clinical CCRCC tumors expressing only HIF-2α were bigger
in size and more resistant to replicative stress compared to
those that expressed both HIF-1α and HIF-2 α. This may
define a critical role for HIF-2α in the biology of VHL -/-
CCRCC enabling greater growth; this demonstrates that in
certain contexts HIF-1α can act as a tumor suppressor (see
also [10, 47]).
Abbreviations
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